NT
The startup develops human antibody therapeutics that block the Nogo-A receptor, which inhibits nerve growth, to promote nerve regeneration in patients with spinal cord injuries. This therapy aims to enhance functional recovery for individuals suffering from severe neurological disorders by facilitating nerve repair.
Updated 18 months ago
Funding
$11.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NHPB
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops human antibody therapeutics that block the Nogo-A receptor, which inhibits nerve growth, to promote nerve regeneration in patients with spinal cord injuries. This therapy aims to enhance functional recovery for individuals suffering from severe neurological disorders by facilitating nerve repair.